Evolus Inc
NASDAQ:EOLS

Watchlist Manager
Evolus Inc Logo
Evolus Inc
NASDAQ:EOLS
Watchlist
Price: 5.08 USD 3.67% Market Closed
Market Cap: 329.3m USD

Operating Margin

-13.3%
Current
Improving
by 6.6%
vs 3-y average of -20%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13.3%
=
Operating Income
$-38.1m
/
Revenue
$285.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-13.3%
=
Operating Income
$-38.1m
/
Revenue
$285.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Evolus Inc
NASDAQ:EOLS
329m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.4B USD
Loading...

Market Distribution

Lower than 75% of companies in the United States of America
Percentile
25th
Based on 14 112 companies
25th percentile
-13.3%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Evolus Inc
Glance View

Market Cap
329.3m USD
Industry
Pharmaceuticals

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. The company is headquartered in Newport Beach, California and currently employs 167 full-time employees. The company went IPO on 2018-02-08. The Company’s first commercial product is Jeuveau, which is an approximately 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. The company offers customers and consumers a compelling value proposition with Jeuveau. BOTOX (onabotulinumtoxinA) is also an approximately 900 kDa botulinum toxin type A complex approved in the United States.

EOLS Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-13.3%
=
Operating Income
$-38.1m
/
Revenue
$285.8m
What is Evolus Inc's current Operating Margin?

The current Operating Margin for Evolus Inc is -13.3%, which is above its 3-year median of -20%.

How has Operating Margin changed over time?

Over the last 3 years, Evolus Inc’s Operating Margin has increased from -47.6% to -13.3%. During this period, it reached a low of -47.6% on Sep 30, 2022 and a high of -10.2% on Dec 31, 2024.

Back to Top